Mechanism of action.

Tumour angiogenesis is essential for cancer cell survival, growth and metastasis. In early 2015, Eisai Pharmaceuticals launched lenvatinib, a triple-targeting tyrosine kinase inhibitor for the treatment of radioiodine refractory differentiated thyroid cancer.

Blue Dog worked with the lenvatinib global brand team and Virgo Health to develop a 3D animation, which demonstrates the process of angiogenesis, introduces lenvatinib and establishes it’s value within the cancer treatment pathway.